成都新诺明生物科技

Chengdu Xinnuoming Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, dedicated to discovering and developing innovative small molecule therapeutics for metabolic diseases and other chronic conditions. The company's core expertise lies in medicinal chemistry and the optimization of oral small molecules to replace or complement existing injectable biologics. Its lead candidate, XNM-001, is a potent and selective oral GLP-1 receptor agonist currently undergoing Phase 1 clinical trials for the treatment of type 2 diabetes and obesity. Xinnuoming was founded by industry experts with extensive backgrounds in global pharmaceutical R&D, aiming to address significant unmet medical needs in the metabolic health landscape.